Breast cancer is a threatening scenario resulting from the development of endometriosis and benign breast disease overlap syndrome: literature review
Open Access
- 1 April 2025
- journal article
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (2) , 206-214
Abstract
Background. According to the National Cancer Registry of Ukraine, mortality from breast cancer (BC) continues to be at the first places in the structure of oncological pathology among the female population. The overlap syndrome of genital endometriosis (GE) and benign breast disease (BBD) can play a significant role in the development of BC. The purpose: using data from modern literature sources, to consider the overlap syndrome of GE and BBD as a precancerous pattern in the development of BC and outline possible steps to solve the problem. Materials and methods. The search and selection of publications was carried out in the PubMed and Google Scholar databases using the following terms: genital endometriosis, benign breast disease, mastopathy, fibrocystic dysplasia, mastalgia, breast cancer, hormone therapy. Results. A convincing link between endometriosis and fibrocystic disease has been established in fertile women: the prevalence of BBD in patients with endometriosis is 36–38 %. Pilot clinical studies have confirmed that in women with endometriosis who received dienogest at a dose of 20 mg/day orally for 24 weeks, a significant decrease in breast size (p < 0.023) and regression of mastopathic changes were observed when assessing the effect of progestogen on the breast using ultrasound. A slight decrease (p = 0.089) in the maximum diameter of the ducts was observed. At the stages of development of the overlap syndrome of GE and BBD with a confirmed increased risk of BC, a complex pathogenetic matrix is formed, the processes in which are often not linear, but can occur in parallel, demonstrating the diversity and unpredictability of biological events. The high percentage of overlap syndrome of GE and BBD confirms the idea of the unity of the origin of pathological changes in target organs and the synchronous development of benign hyperplastic processes in them. Conclusions. It is advisable to consider hyperplastic diseases as a generalized process in the reproductive system, and to develop single therapeutic tactics when gynecological pathology is combined with breast diseases. The overlap syndrome of GE and BBD, which is a proven factor of increased risk of breast cancer, requires responsible and coordinated teamwork of endocrinologists, mammologists and obstetricians-gynecologists, which is designed to create necessary conditions for a significant improvement in the effectiveness of therapy. The development in the near future of an algorithm for clinical monitoring of patients with overlap syndrome of GE and BBD will be a logical and justified step, because early diagnosis of BC provides better treatment results and an increase in the quality of life of patients.Keywords
This publication has 69 references indexed in Scilit:
- RANK/RANKL Signaling Pathway in Breast Development and Cancer2025
- Estrogens and breast cancerAnnals of Oncology, 2024
- Benign Breast Disease and Breast Cancer Risk in the Percutaneous Biopsy EraJAMA Surgery, 2024
- Evaluation of long-term efficacy and safety of dienogest in patients with chronic cyclic pelvic pain associated with endometriosisArchives of Gynecology and Obstetrics, 2023
- Current Medical Therapy for Adenomyosis: From Bench to BedsideDrugs, 2023
- Genomic characterisation of the overlap of endometriosis with 76 comorbidities identifies pleiotropic and causal mechanisms underlying disease riskHuman Genetics, 2023
- Effects of Dienogest on breasts of women of reproductive age and women in menopausal transition: A cohort studyInternational Journal of Gynecology & Obstetrics, 2023
- Pathophysiology of endometriosis-associated pain: A review of pelvic and central nervous system mechanismsBest Practice & Research Clinical Obstetrics & Gynaecology, 2018
- Medical treatment of endometriosis-related painBest Practice & Research Clinical Obstetrics & Gynaecology, 2018
- Dydrogesterone and other progestins in benign breast disease: an overviewArchives of Gynecology and Obstetrics, 2010